GTX-102 is a human ubiquitin-protein ligase E3A antisense (UBE3A-AS) transcript-targeted antisense oligonucleotide (ASO) intended for the treatment of Angelman syndrome (AS). Findings from the Phase 1/2 dose-finding study (GTX-102-001) suggest a positive efficacy signal and favorable benefit risk profile for GTX-102 in pediatric patients with AS. The purpose of this study is to investigate the efficacy and safety of GTX-102 in AS.
What is the full name of this clinical trial?
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome